A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation) caused by herpes simplex virus (HSV) does not ...

Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before ...

BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage ...

A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation), caused by herpes simplex virus (HSV) does not ...

Please provide your email address to receive an email when new articles are posted on . Herpes simplex encephalitis (HSE) is likely the most serious herpes infection patients can face. Treatment ...

Defects in a single protein involved in cell death may impair the immune system's ability to combat a herpes viral infection in the central nervous system, scientists have found in new research that ...

This case illustrates many of the diagnostic challenges that may be encountered in patients presenting with herpes simplex infection of the brain. The patient had presented with transient focal ...

The herpes simplex virus-1 can sometimes cause a dangerous brain infection. Combining an anti-inflammatory and an antiviral could help in these cases, report scientists with the Rajewsky and ...

About 3.7 billion people carry the herpes simplex virus-1 in our nerve cells where it lies quiescent until triggered by stress or injury. When activated, its symptoms are usually mild, limited to cold ...

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

The MarketWatch News Department was not involved in the creation of this content. BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical ...